Dengue is currently the most import

Dengue is currently the most important mosquito-borne viral disease globally. The incidence of dengue has increased substantially over recent decades, with about half of the world’s population now at risk of infection. Vector control is currently the main strategy to reduce dengue virus transmission; however, vector control has not halted the spread of Aedes aegypti, the main dengue vector, and of dengue outbreaks. Promising new vector control technologies could potentially save billions of dollars annually in averted medical costs, productivity losses, and premature deaths. While still under development, genetically modified (GM) sterile insect methods are a potentially promising approach to control dengue. GM mosquitoes have been developed with the goal of producing offspring that die in the early developmental stage, and reducing the mosquito population below the dengue transmission threshold. Here, we present a framework and the main components of an economic analysis to assess GM mosquito technologies. Combining data from various dengue-endemic countries, we generate a mathematical model of costs and benefits and calibrated it with available evidence. We discuss the main assumptions, results, and caveats around these estimates.